Status:
COMPLETED
Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder.
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborating Sponsors:
Otsuka America Pharmaceutical
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
A Multicenter, Double-blind 16 Week Study on the augmentation of atypical antipsychotic with Aripiprazole in patients with Schizophrenia with inadequate response to antipsychotic treatment.
Eligibility Criteria
Inclusion
- Patient with diagnosis of chronic Schizophrenia or Schizoaffective disorder
- Stable symptoms and dose of Quetiapine or Risperidone
Exclusion
- First diagnosis in the past year
- Significant risk of suicide or meet DSM-IV-TR criteria for substance abuse
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
323 Patients enrolled
Trial Details
Trial ID
NCT00325689
Start Date
July 1 2006
End Date
October 1 2007
Last Update
November 8 2013
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
K & S Professional Research Services, Llc
Little Rock, Arkansas, United States, 72201
2
Comprehensive Neuroscience, Inc.
Cerritos, California, United States, 90703
3
Atp Clinical Research, Inc.
Costa Mesa, California, United States, 92626
4
Collaborative Neuroscience Network, Inc.
Garden Grove, California, United States, 92845